JHJohn B. Hagan

John B. Hagan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


John B. Hagan has a total of 83 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Biphasic, refractory, and life-threatening anaphylactic reactions to iodinated contrast media

    by Hans Gao, Lauren Lu, Eduardo Saadi Neto, Jennifer S. McDonald, Robert J. McDonald, Aidan F. Mullan, John B. Hagan, James T.C. Li, Ronna L. Campbell


  • Step Down From Scheduled Inhaled Corticosteroids (ICS) Plus As-Needed Fast-Acting Beta-Agonists (FABA) to As-Needed ICS/FABA: A Systematic Review and Meta-Analysis

    by Ricardo J. Estrada-Mendizabal, John B. Hagan, Alex Wonnaparhown, Catherine M. Freeman, Christina G. Kwong, Gerald W. Volcheck, Lisa A. Marks, Derek K. Chu, Matthew A. Rank


  • Open Access

    Risk for Postmarket Black Box Warnings in FDA-Approved Monoclonal Antibodies

    by John B. Hagan, Elizabeth Ender, Rohit D. Divekar, Thanai Pongdee, Matthew A. Rank


  • Urinary Leukotriene E4 to Determine Aspirin Intolerance in Asthma: A Systematic Review and Meta-Analysis

    by John B. Hagan, Tanya M. Laidlaw, Rohit Divekar, Erin K. O'BRien, Hirohito Kita, Gerald W. Volcheck, Christina R. Hagan, Devyani Lal, Harry G. Teaford, Patricia J. Erwin, et al.


  • Assessing the Risks and Benefits of Step-Down Asthma Care: A Case-Based Approach

    by John B. Hagan, Matthew A. Rank

    Guidelines have called for pharmacologic stepped care to improve asthma treatment. Therapeutic options which have been approved provide physicians and their patients alternatives for stepping up asthma treatment to achieve control. However, few studies have been performed to identify and characterize procedures for optimal stepping-down treatment in patients with asthma. The resulting uncertainty as well as a lack of prioritization for asthma reassessment once control has been maintained has led to a lack of well-defined procedures for stepping down asthma treatment. However, recent studies provide guidance regarding the risks of stepping down asthma medications. This review uses case-based examples to demonstrate how health care providers may engage patients in discussions regarding guideline recommendations to promote individualized asthma care.


  • Three‐dimensional volumetric computed tomographic scoring as an objective outcome measure for chronic rhinosinusitis: clinical correlations and comparison to Lund‐Mackay scoring

    by John F. Pallanch, Lifeng Yu, David Delone, Rich Robb, David R. Holmes, Jon Camp, Phil Edwards, Cynthia H. McCollough, Jens Ponikau, Amy C. Dearking, et al.

    Background: We aimed to test the hypothesis that three‐dimensional (3D) volume‐based scoring of computed tomography (CT) images of the paranasal sinuses was superior to Lund‐Mackay CT scoring of disease severity in chronic rhinosinusitis (CRS). We determined correlation between changes in CT scores (using each scoring system) with changes in other measures of disease severity (symptoms, endoscopic scoring, and quality of life) in patients with CRS treated with triamcinolone.Methods: The study group comprised 48 adult subjects with CRS. Baseline symptoms and quality of life were assessed. Endoscopy and CT scans were performed. Patients received a single systemic dose of intramuscular triamcinolone and were reevaluated 1 month later. Strengths of the correlations between changes in CT scores and changes in CRS signs and symptoms and quality of life were determined.Results: We observed some variability in degree of improvement for the different symptom, endoscopic, and quality‐of‐life parameters after treatment. Improvement of parameters was significantly correlated with improvement in CT disease score using both CT scoring methods. However, volumetric CT scoring had greater correlation with these parameters than Lund‐Mackay scoring.Conclusion: Volumetric scoring exhibited higher degree of correlation than Lund‐Mackay scoring when comparing improvement in CT score with improvement in score for symptoms, endoscopic exam, and quality of life in this group of patients who received beneficial medical treatment for CRS.


  • Urinary fluticasone propionate-17beta-carboxylic acid to assess asthma therapy adherence

    by John B. Hagan, Brian C. Netzel, Marc R. Matthews, Nichole L. Korpi-Steiner, Ravinder J. Singh

    Although the National Asthma Education and Prevention Program Expert Panel Report 3 recommends referral to specialists to address adherence, guidelines do not provide a tool to determine nonadherence. This study was designed to prospectively evaluate the characteristics of urinary analysis of fluticasone propionate-17beta-carboxylic acid (FP17betaCA) as a test to verify if a specific patient has not taken fluticasone propionate (FP) within 16‐24 hours. Urine of asthmatic subjects was prospectively analyzed 16‐24 hours after witnessed administration of orally inhaled FP using liquid chromatography tandem mass spectrometry (LC-MS/MS) analysis; limit of quantitation was 10.3 pg/mL. Results were compared with those from asthmatic subjects not receiving inhaled FP. Thirty asthmatic subjects receiving inhaled FP (2 oral inhalations of FP at 110 micrograms each or 1 oral inhalation twice daily of fluticasone and salmeterol in fixed combination at 250/50 micrograms for 1 week) were compared with 30 asthmatic subjects not receiving FP. FP17betaCA was detected in the urine of 30 of 30 asthmatic subjects receiving FP (median, interquartile range [IQR; 413.5, 212.8‐1230.0] range 12.4‐3290.0 pg/mL [corrected for urine creatinine: median, IQR {576.2, 188.1‐1306.6} range 6.3‐5425.9 ng/g Cr]) and was undetectable in 30 of 30 subjects not receiving inhaled FP. The sensitivity and specificity of LC-MS/MS to detect FP17betaCA in urine were 100% (95% exact binomial confidence interval, 88‐100) and 100% (95% exact binomial confidence interval, 88‐100), respectively. Analysis of FP17betaCA in urine provides a sensitive method that may be used to verify that a specific patient may not have administered FP within a 16- to 24-hour window before testing.


  • Safety ofL-proline as a stabilizer for immunoglobulin products

    by John B Hagan, Richard L Wasserman, Jeffrey S Baggish, Martin O Spycher, Melvin Berger, Vandana Shashi, Emanuel Lohrmann, Kathleen E Sullivan

    Privigen(®) (immune globulin intravenous [human], 10% liquid) and Hizentra(®) (immune globulin subcutaneous [human], 20% liquid) are stabilized by proline. The clinical implications of administering proline-containing immunoglobulin products to patients with defects of proline metabolism have not been addressed; Privigen and Hizentra are contraindicated in these patients. Some patients with chromosome 22q11.2 deletion syndrome have elevated proline levels; however, only 3-4% of patients also have an immunodeficiency that requires IgG therapy. This review summarizes the evidence related to the safety and pharmacokinetics of proline assessed in Privigen and Hizentra preclinical and clinical studies, and subsequent implications for patients with defects in proline metabolism. Clinical data indicate that proline does not accumulate after Privigen or Hizentra treatment and is not associated with adverse events. There is no evidence to suggest that patients with defects of proline metabolism would be affected by transient elevations in plasma proline following Privigen and/or Hizentra treatment.


  • Analysis of fluticasone propionate in induced sputum by mass spectrometry

    by John B. Hagan, Robert L. Taylor, Hirohito Kita, Ravinder J. Singh

    Although evaluation of induced sputum has shown promise as a marker of eosinophilic airway inflammation in asthmatic subjects, most studies, to date, do not adequately address the potential effect that inhaled corticosteroids may have on sputum eosinophilia. This study was designed to prospectively evaluate analysis of fluticasone propionate (FP) in whole sputum by mass spectrometry as a tool to determine recent administration of inhaled FP. Induced sputum of nonsmoking asthmatic subjects was prospectively analyzed 16‐24 hours after witnessed administration of orally inhaled FP. FP was extracted from whole sputum via an acetonitrile protein precipitation followed by methylene chloride liquid extraction of the supernatant (AB 4000; AB Sciex). A portion of the reconstituted sample was analyzed by liquid chromatography tandem mass spectrometry using a triple quad tandem mass spectrometer. Results were compared with those from nonsmoking asthmatic subjects not receiving inhaled FP. Twenty-two asthmatic subjects on FP and 9 asthmatic subjects without FP underwent sputum induction 16‐24 hours following witnessed administration of FP. Sufficient sputum for analysis was obtained from 30 of 31 subjects. FP was detected in 22 of 22 asthmatic subjects receiving FP (range, 29‐133,000 pg/mL) and was undetectable in 8 of 8 subjects not receiving FP. The sensitivity and specificity of tandem mass spectrometry's ability to detect FP in sputum was 100% and 100%, respectively. Analysis of FP in induced sputum is a reliable method to verify recent administration of inhaled FP. Induced asthmatic sputum from one induction may be used to concomitantly assess sputum eosinophilia as well as recent administration of FP.


  • Open Access

    Assessment of Synthetic Glucocorticoids in Asthmatic Sputum

    by John B. Hagan, Robert L. Taylor, Ravinder J. Singh

    Nonadherence with anti-inflammatory treatment is a frequent cause of continued symptoms in asthmatic patients. Clinical assessments including patient-reported medication administration may provide the asthma specialist incomplete information regarding actual adherence to anti-inflammatory medications. The objective of this report was to describe the first case where adherence to inhaled asthma therapy was assessed by direct analysis of glucocorticoids in induced sputum. The patient's blood, urine, and sputum were tested for synthetic corticosteroids using mass spectrometry. To evaluate a clinical suspicion of poor adherence, sputum, urine, and blood were used to assess for current compliance to medication use. We report a case where asthma specialists attributed poorly controlled asthma to nonadherence to medical therapy. After modification of the medical regimen, adherence with oral and inhaled steroids was assessed–via examination of the urine, blood, and sputum. Direct analysis of glucocorticoids in sputum is feasible and in theory could provide a novel tool to document current medication adherence. Concomitant assessment of glucocorticoids and eosinophils in the same induced sputum specimen could provide insight into possible steroid resistance in select referral patients with difficult asthma.